It's not just Charles Lieber: NI­H's on­go­ing in­ves­ti­ga­tion has swept up 54 sci­en­tists who vi­o­lat­ed rules about for­eign ties

Michael Lauer NIH

The NIH’s work­ing group for for­eign in­flu­ences on re­search in­tegri­ty has opened cas­es against 189 sci­en­tists sus­pect­ed of vi­o­la­tions re­lat­ed to over­seas ties since launch­ing an on­go­ing, sweep­ing in­ves­ti­ga­tion al­most two years ago, new­ly avail­able sta­tis­tics showed, lead­ing to the ter­mi­na­tions and res­ig­na­tions of 54 sci­en­tists.

Of those who have been in­ves­ti­gat­ed, 41% have al­so been re­moved from the NIH sys­tem, barred from seek­ing fur­ther grants. Michael Lauer, NIH’s head of ex­tra­mur­al re­search, pre­sent­ed a com­pre­hen­sive set of these and oth­er num­bers in a vir­tu­al up­date on Fri­day, just a day af­ter Charles Lieber — the for­mer head of Har­vard’s chem­istry de­part­ment — was in­dict­ed in fed­er­al court for ly­ing about his Chi­nese con­nec­tions.

While high-pro­file cas­es like Lieber’s, as well as those at MD An­der­son, Emory Uni­ver­si­ty and Mof­fitt be­fore him, have gripped the bio­med­ical field, they mere­ly rep­re­sent in­di­vid­ual snap­shots of when in­sti­tu­tions re­spond to the NIH’s warn­ings about hid­den for­eign ties. The of­fi­cial da­ta shine light on the broad­er pic­ture.

Fran­cis Collins NIH

For one, more could be com­ing. The NIH has iden­ti­fied 399 sci­en­tists of pos­si­ble con­cern in to­tal, 251 of whom screened “pos­i­tive,” with an­oth­er 72 “pend­ing.”

Agency di­rec­tor Fran­cis Collins called that pic­ture “sober­ing,” ac­cord­ing to Sci­ence, which first re­port­ed on Lauer’s re­marks.

At the heart of the is­sue, Lauer high­light­ed, isn’t that US re­searchers are col­lab­o­rat­ing with in­ves­ti­ga­tors in for­eign coun­tries. Rather, it’s of­ten about NIH-backed sci­en­tists’ fail­ure to dis­close sig­nif­i­cant re­sources from al­ter­na­tive sources, con­flicts of in­ter­est or patents. In cer­tain cas­es, there were even peer re­view vi­o­la­tions.

Over­all, Chi­na stood out as the top coun­try pro­vid­ing for­eign sup­port to sci­en­tists, ei­ther re­flect­ing or con­firm­ing the long­stand­ing rhetoric on aca­d­e­m­ic es­pi­onage. Pre­sum­ably through the Thou­sand Tal­ents Pro­gram, Chi­nese fund­ing was in­volved in 93% of the cas­es.

It may thus be un­sur­pris­ing that the vast ma­jor­i­ty of cas­es in­volve an Asian man in his 50s, al­though 14% of the in­ves­ti­ga­tions cen­tered around whites. On av­er­age, the NIH has is­sued $678,000 in grant sup­port to each of these sci­en­tists, who are spread across 27 states and 59 cities.

But there is hope that in­sti­tu­tions are grow­ing more aware of the prob­lems — which might not have pre­vi­ous­ly been con­sid­ered se­ri­ous un­til the FBI and the NIH cracked down on them — and tak­ing ac­tions against non-com­pli­ance. As part of their ef­forts, the NIH has con­tact­ed 87 uni­ver­si­ties or re­search cen­ters; slight­ly more than half men­tioned they are im­ple­ment­ing new mea­sures.

In a nod to con­cerns that the height­ened sen­ti­ments are stok­ing fears among sci­en­tists of Asian her­itage who fear they may be tar­get­ed, Lauer made sure to tuck this re­as­sur­ance to the end of his slides:

We re­it­er­ate the im­por­tance of the con­tri­bu­tion of for­eign sci­en­tists to bio­med­ical re­search; we must not cre­ate a cli­mate that is un­wel­com­ing to them.

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly set to in­vest $2.1B in home state man­u­fac­tur­ing boost

Eli Lilly is looking to expand its footprint in its home Hoosier State by making a major investment in manufacturing.

The pharma is investing $2.1 billion in two new manufacturing sites at Indiana’s LEAP Lebanon Innovation and Research District in Boone County, northwest of Lilly’s headquarters in Indianapolis.

The two new facilities will expand Lilly’s manufacturing network for active ingredients and new therapeutic modalities, including genetic medicines, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

US sees spike in Paxlovid us­age as Mer­ck­'s mol­nupi­ravir and As­traZeneca's Evusheld are slow­er off the shelf

New data from HHS show that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing a streak of increased usage of the pill, and signaling not only rising case numbers but more awareness of how to access it.

In comparison to this week, about 670,000 courses of the Pfizer pill have been administered across the first five months since Paxlovid has been on the US market, averaging about 33,000 courses administered per week in that time.

Pfiz­er and CD­MOs ramp up Paxlovid man­u­fac­tur­ing with Kala­ma­zoo plant ex­pan­sion lead­ing the way

As the Covid-19 pandemic continues to evolve, pharma companies and manufacturers are exploring how to step up production on antivirals.

Pfizer is planning to expand its Kalamazoo-area facility to increase manufacturing capabilities for the oral Covid-19 antiviral Paxlovid, according to a report from Michigan-based news site MLive. The expansion of the facility, which serves as Pfizer’s largest manufacturing location, is expected to create hundreds of “high-skilled” STEM jobs, MLive reported. No details about the project’s cost and timeline have been released, but according to MLive, Pfizer will announce the details of the expansion at some point in early June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

FDA spells out the rules and re­stric­tions for states seek­ing to im­port drugs from Cana­da

The FDA is offering more of an explanation of the guardrails around its program that may soon allow states to import prescription drugs in some select circumstances from Canada, but only if such imports will result in significant cost reductions for consumers.

While the agency has yet to sign off on any of the 5 state plans in the works so far, and PhRMA’s suit to block the Trump-era rule allowing such imports is stalled, the new Q&A guidance spells out the various restrictions that states will have to abide by, potentially signaling that a state approval is coming.

Robert Califf (Michael Brochstein/Sipa USA via AP Images)

House Re­pub­li­cans at­tack Chi­na-on­ly da­ta in FDA sub­mis­sions, seek new in­ves­ti­ga­tion in­to re­search in­spec­tions

Three Republican representatives are calling on the FDA to take a closer look at the applications including only clinical data from China.

The letter to FDA commissioner Rob Califf late last week comes as the agency recently rejected Eli Lilly’s anti-PD-1 antibody, which attempted to bring China-only data but ran into a bruising adcomm that may crush the hopes of any other companies looking to bring cheaper follow-ons based only on Chinese data.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Pfizer CEO Albert Bourla at the World Economic Forum (Gian Ehrenzeller/Keystone via AP Images)

All about ac­cess: Pfiz­er moves to a non-prof­it mod­el for drug sales in 45 low­er-in­come coun­tries

Leading the way to increase access to cheaper drugs worldwide, Pfizer said Wednesday it will provide all current and future patent-protected medicines and vaccines available in the US or EU on a not-for-profit basis to about 1.2 billion people in 45 lower-income countries.

Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to sign on to this accord, which will also seek to blaze new paths for quick and efficient regulatory and procurement processes to reduce the usual delays in making new medicines and vaccines available in these countries.

Almirall is tapping artificial intelligence on behalf of its sales force for insights and efficiencies. (via Shutterstock)

Almi­rall rolls out sales rep ar­ti­fi­cial in­tel­li­gence sys­tem, cut­ting pre-call prep and 'wind­shield time'

Dermatology specialty pharma Almirall is making its sales reps smarter. Not with extra training or educational courses, but instead with artificial intelligence tools.

It began a soft launch of a sales rep AI and machine learning platform it calls Polaris last August in one of its 7 US coverage regions. The platform from Aktana gathers information from across Almirall internal sources and external ones – such as claims and prescribing data – to generate insights for reps. Now, instead of spending hours prepping for a sales call, Polaris can generate details about a physician’s preferences, past behaviors and prescription habits for reps in minutes, said Almirall head of commercial operations Vincent Cerio.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Te­va, Al­ler­gan reach yet an­oth­er opi­oid set­tle­ment — ef­fec­tive­ly end­ing WV tri­al

Teva and Allergan have reached settlements with multiple states over their involvement in the opioid crisis. Their latest is worth 9 figures.

West Virginia attorney general Patrick Morrisey announced the newest settlement, worth $161.5 million, at a press conference on Wednesday. The deal would resolve claims that the companies helped fuel the state’s opioid epidemic. If it goes through, it could become the largest state-negotiated settlement in West Virginia’s history, according to Reuters.